Cooley advised Lightstone Ventures on the deal.
Lightstone Ventures, a global venture capital firm investing in biotech and medtech companies, announced the closing of Lightstone Ventures III, an over-subscribed fund that exceeded its targeted raise with $375 million in capital commitments.
The new fund will invest in early-stage companies developing high-impact therapeutics and technologies that have the potential to change patients’ lives.
Since its inception in 2012, Lightstone has invested in more than 30 companies, all of which share a commitment to translating scientific breakthroughs into clinically and commercially meaningful therapies and technologies.
The Cooley team was led by Nicole Peppe (Picture), Casey Schulte and Rachel Goddard. Additional assistance was provided by Bernard Hatcher, Stephanie Gentile, Paul Roberts, Sean Donahue and Molly Kirwan.
Involved fees earner: Sean Donahue – Cooley LLP; Stephanie Gentile – Cooley LLP; Rachel Goddard – Cooley LLP; Bernard Hatcher – Cooley LLP; Molly Kirwan – Cooley LLP; Nicole Peppe – Cooley LLP; Paul Roberts – Cooley LLP; Casey Schulte – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Lightstone Ventures;